Tara Miller
Optometrist · Scottsdale, AZNPI 1619107075
Payments from drug & device makers
Across 74 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$397
- Bausch & Lomb Americas Inc.$238
- Oyster Point Pharma, Inc.$180
- Alcon$134
- Kala Pharmaceuticals, Inc.$108
- Bausch & Lomb, A Division Of Bausch Health US, LLC$99
- plus $491 from 13 others
What the payments were for
- Food & beverage$1,648100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,648 in reported general payments places this provider in the 70th percentile of 1,134 optometrist providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 58 | $69,168 |
| XiidraLifitegrast | 30 | $42,424 |
| LumiganBimatoprost | 54 | $35,284 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $13,999 |
| Cyclosporine | 15 | $12,376 |
| VyzultaLatanoprostene Bunod | 16 | $11,262 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $9,899 |
| Timolol Maleate | 132 | $5,184 |
| Travoprost | 37 | $4,155 |
| Latanoprost | 329 | $3,968 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $1,174 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 14 | $571 |
| Doxycycline Monohydrate | 25 | $526 |
| Doxycycline Hyclate | 12 | $420 |
| Brimonidine Tartrate | 26 | $395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $54 | $114,351129 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $238 | $53,68646 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $24 | $13,99918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Scottsdale
- Marc BloomensteinScottsdale$2.3M
- Stephen CohenScottsdale$32K
- Andrew ZagelbaumScottsdale$25K
- Amanda GoldbergScottsdale$7K
- Daxa LadScottsdale$6K
- Stephanie WooLake Havasu City$540K
- Kevin HelmuthSacaton$281K
- Christina SorensonGlendale$181K
- Jashpal RajasansiGilbert$120K
- Michelle Marie MijaresFort Defiance$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.